You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
石藥集團(01093.HK)3款產品於中國全國藥品集中採購招標中擬中選
阿思達克 01-20 09:51

石藥集團(01093.HK)公布,公司三款產品於中國全國藥品集中採購招標中擬中選,有關藥物分別為阿莫西林膠囊,擬中選價格2.16元人民幣(下同),供應省份為內蒙古、浙江、四川、西藏及陝西。阿奇霉素片擬中選價格4.98元,供應省份為北京、天津、浙江、湖南、廣東、貴州、陝西、青海及新疆(含兵團)。注射用紫杉醇(白蛋白結合型)擬中選價格747元,供應省份為河北、山西、遼寧、吉林、黑龍江、江蘇、湖南、廣東、貴州、陝西及青海。

公司表示,有關產品於招標中的擬中選價格均低於其各自於市場的現行售價,惟有關產品於招標中成功中選將有助提高該等產品的銷量。公司另外兩款產品鹽酸克林霉素膠囊及頭孢氨芐膠囊則未有於招標中成功中選。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account